Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.64 |
| ▸ | CA1 known ✓ | P00915 | 2/20 | 0.61 |
| ▸ | GPR84 | Q9NQS5 | 8/20 | 0.63 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.63 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.55 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL830879 | 1.00 | CA2 (0.64) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL6561695 | 1.00 | CA2 (0.64) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL9355567 | 1.00 | CA2 (0.64) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL29800325 | 1.00 | CA2 (0.64) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL10913274 | 1.00 | CA2 (0.64) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL7202633 | 1.00 | CA2 (0.64) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL1233071 | 1.00 | CA2 (0.64) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL10911647 | 0.98 | CA1 (0.63) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL23391732 | 0.96 | GPR84 (0.63) | CA2GPR84FFAR1CA1NFKB1 | |
| SCHEMBL11812812 | 0.96 | GPR84 (0.63) | CA2GPR84FFAR1CA1NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1917973-A1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | Teva Pharmaceutical Industries Ltd (IL) | 2008-05-07 | — | — | EP | claimed |
| EP-1864677-B1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | TEVA PHARMA (IL) | 2008-01-02 | — | — | EP | claimed |
| EP-1864677-A1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | Teva Pharmaceutical Industries Ltd (IL) | 2007-12-12 | — | — | EP | claimed |
| CN-118829416-A | Composition (III) | 西姆莱斯股份公司 | 2024-10-22 | — | — | CN | disclosed |
| EP-2395838-B1 | STABLE PHARMACEUTICAL COMPOSITION FOR ATHEROSCLEROSIS | CADILA PHARMACEUTICALS LTD (IN) | 2018-07-25 | — | — | EP | disclosed |
| US-9789187-B2 | Stable pharmaceutical composition for atherosclerosis | CADILA PHARMACEUTICALS LIMITED (IN) | 2017-10-17 | — | — | US | disclosed |
| US-20120027849-A1 | STABLE PHARMACEUTICAL COMPOSITION FOR ATHEROSCLEROSIS | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-02 | — | — | US | disclosed |
| EP-1917973-A1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | Teva Pharmaceutical Industries Ltd (IL) | 2008-05-07 | — | — | EP | disclosed |
| EP-1864677-B1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | TEVA PHARMA (IL) | 2008-01-02 | — | — | EP | disclosed |
| WO-2007142628-A1 | STABLE FORMULATION COMPRISING MOISTURE SENSITIVE DRUG/S AND MANUFACTURING PROCEDURE THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-13 | — | — | WO | disclosed |
| EP-1864677-A1 | Stable formulation comprising a moisture sensitive drug and manufacturing procedure thereof | Teva Pharmaceutical Industries Ltd (IL) | 2007-12-12 | — | — | EP | disclosed |
| US-20070281000-A1 | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-12-06 | — | — | US | disclosed |